Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

307 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The ALSFRSr predicts survival time in an ALS clinic population.
Kaufmann P, Levy G, Thompson JL, Delbene ML, Battista V, Gordon PH, Rowland LP, Levin B, Mitsumoto H. Kaufmann P, et al. Among authors: mitsumoto h. Neurology. 2005 Jan 11;64(1):38-43. doi: 10.1212/01.WNL.0000148648.38313.64. Neurology. 2005. PMID: 15642901
The natural history of primary lateral sclerosis.
Gordon PH, Cheng B, Katz IB, Pinto M, Hays AP, Mitsumoto H, Rowland LP. Gordon PH, et al. Among authors: mitsumoto h. Neurology. 2006 Mar 14;66(5):647-53. doi: 10.1212/01.wnl.0000200962.94777.71. Neurology. 2006. PMID: 16534101
A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS.
Levy G, Kaufmann P, Buchsbaum R, Montes J, Barsdorf A, Arbing R, Battista V, Zhou X, Mitsumoto H, Levin B, Thompson JL. Levy G, et al. Among authors: mitsumoto h. Neurology. 2006 Mar 14;66(5):660-3. doi: 10.1212/01.wnl.0000201182.60750.66. Neurology. 2006. PMID: 16534103 Clinical Trial.
Quantitative objective markers for upper and lower motor neuron dysfunction in ALS.
Mitsumoto H, Ulug AM, Pullman SL, Gooch CL, Chan S, Tang MX, Mao X, Hays AP, Floyd AG, Battista V, Montes J, Hayes S, Dashnaw S, Kaufmann P, Gordon PH, Hirsch J, Levin B, Rowland LP, Shungu DC. Mitsumoto H, et al. Neurology. 2007 Apr 24;68(17):1402-10. doi: 10.1212/01.wnl.0000260065.57832.87. Neurology. 2007. PMID: 17452585
Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III.
Kaufmann P, Thompson JL, Levy G, Buchsbaum R, Shefner J, Krivickas LS, Katz J, Rollins Y, Barohn RJ, Jackson CE, Tiryaki E, Lomen-Hoerth C, Armon C, Tandan R, Rudnicki SA, Rezania K, Sufit R, Pestronk A, Novella SP, Heiman-Patterson T, Kasarskis EJ, Pioro EP, Montes J, Arbing R, Vecchio D, Barsdorf A, Mitsumoto H, Levin B; QALS Study Group. Kaufmann P, et al. Among authors: mitsumoto h. Ann Neurol. 2009 Aug;66(2):235-44. doi: 10.1002/ana.21743. Ann Neurol. 2009. PMID: 19743457 Free PMC article. Clinical Trial.
Wish to die in end-stage ALS.
Albert SM, Rabkin JG, Del Bene ML, Tider T, O'Sullivan I, Rowland LP, Mitsumoto H. Albert SM, et al. Among authors: mitsumoto h. Neurology. 2005 Jul 12;65(1):68-74. doi: 10.1212/01.wnl.0000168161.54833.bb. Neurology. 2005. PMID: 16009887 Free PMC article.
307 results